Positions

Selected Publications

Chapter

Year Title Altmetric
2015 Interaction of Chemotherapy and Radiation.  63-79.e4. 2015

Research Overview

  • Many cancer therapies attack cellular DNA to cause DNA damage. The DNA double strand break (DSB) is the most critical form of DNA damage that induces both normal and cancer cell death if left unrepaired. My research interests involve the targeting of DNA repair pathways to enhance the therapeutic ratio. We aim to discover novel strategies to augment DNA repair pathways to specifically protect normal cells from DNA damage while reducing DNA repair capacity to convert cancer cells to become more susceptible to DNA damaging agents. Ultimately, we hope to translate our work into the clinic to deferentially treat cancer while sparing normal cells to maintain quality of life.

    Keywords - nanostring, profiling, DNA damage, DNA repair, EGFR, cancer, PARP, apoptosis, brain, protection, GSK3
  • Principal Investigator On

  • Private Grant  awarded by ELI LILLY AND COMPANY 2019 - 2026
  • Private Grant  awarded by ARCUS BIOSCIENCES INC 2020 - 2025
  • Private Grant  awarded by ELI LILLY AND COMPANY 2019 - 2024
  • Private Grant  awarded by PUMA BIOTECHNOLOGY, INC. 2019 - 2024
  • Private Grant  awarded by ELEVATION ONCOLOGY INC. 2021 - 2024
  • UAB 1846: A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes  awarded by Johns Hopkins University 2019 - 2023
  • Phase IB Trial of Radium-223 and Niraparib in Patients with Castrate Resistant Prostate Cancer  awarded by THOMAS JEFFERSON UNIVERSITY - NEW 2018 - 2023
  • Private Grant  awarded by ELI LILLY AND COMPANY 2020 - 2023
  • Private Grant  awarded by PROSTATE CANCER CLINICAL TRIALS CONSORTIUM, LLC 2017 - 2022
  • Private Grant  awarded by PUMA BIOTECHNOLOGY, INC. 2020 - 2022
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology 2017 - 2021
  • Comprehensive Cancer Center Core Support Grant - Experimental Therapeutics Program  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Comprehensive Cancer Center Core Support Grant - Experimental Therapeutics Program  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Private Grant  awarded by CLOVIS ONCOLOGY 2017 - 2021
  • Private Grant  awarded by CLOVIS ONCOLOGY 2017 - 2021
  • Private Grant  awarded by ASTRAZENECA AB 2018 - 2020
  • Mutant p53 Reactivation as a Targeted Approach for Radio-Sensitization of Malignancies Harboring Disruptive Mutations in TP53 Gene.  awarded by Radiological Society of North America 2019 - 2020
  • Exploiting TNBC Vulnerabilities Via Rationally Combined Therapies  awarded by American Association for Cancer Research 2015 - 2019
  • Private Grant  awarded by ELI LILLY AND COMPANY 2016 - 2019
  • Private Grant  awarded by ELI LILLY AND COMPANY 2016 - 2019
  • Biomarkers for Detection of Renal Cell Carcinoma  awarded by American Cancer Society, Inc. 2017 - 2019
  • Comprehensive Cancer Center Core Support Grant - Experimental Therapeutics Program  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2017 - 2018
  • Private Grant  awarded by ELI LILLY AND COMPANY 2016 - 2018
  • Private Grant  awarded by ELI LILLY AND COMPANY 2013 - 2017
  • DNA Repair Independent Mechanisms of HER2+ Tumor Sensitivity to PARP Inhibition  awarded by Komen (Susan G.) Breast Cancer Foundation 2013 - 2017
  • Mechanisms by Which GSK3B Inhibition Enhances Nonhomologous End-Joining Repair  awarded by GABRIELLE'S ANGELS 2011 - 2015
  • Private Grant  awarded by ABBOTT LABORATORIES 2012 - 2014
  • HER2 Overexpression Confers Susceptibility to PARP Inhibition  awarded by American Association for Cancer Research 2012 - 2014
  • Elevated NF-kB Signaling in Breast Cancers of African American Women  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 2013
  • Targeting Homology-Directed Recombinational Repair (HDR) of Chromosomal Breaks to Sensitize Prostate Cancer Cells to Poly (ADP-Ribose) Polymerase (PARP) Inhibition  awarded by DOD - Department of Defense 2010 - 2013
  • Can Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling Induce Synthetic Lethality with Poly (ADP-Ribose) Polymerase Inhibition (PARPi) by Generating a DNA Repair Defect?  awarded by Kimmel (Sidney) Foundation for Cancer Research 2011 - 2013
  • Investigator On

  • Clinical and Molecular Biomarkers of Endpoints in Pediatric Renal Transplantation  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2020 - 2025
  • Integrating Genomic Risk Assessment for Chronic Disease Management in a Diverse Population  awarded by National Human Genome Research Institute/NIH/DHHS 2020 - 2025
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University 2020 - 2025
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2020 - 2025
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS 2019 - 2025
  • TBCRC 050 UAB 17112-A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer  awarded by Johns Hopkins University 2019 - 2024
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2019 - 2024
  • NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019 - 2024
  • Private Grant  awarded by VARIAN MEDICAL SYSTEMS, INC. 2019 - 2023
  • Mechanism of Ultraviolet Radiation Induced Immune Tolerance  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2018 - 2023
  • American Society of Clinical Oncology survey on COVID19 in Oncology Registry  awarded by American Society of Clinical Oncology 2020 - 2022
  • A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer  awarded by University of Florida 2020 - 2022
  • Quantitative Imaging To Personalize Therapy in Her2 Breast Cancer  awarded by American Cancer Society, Inc. 2019 - 2022
  • RTOG Foundation Master Service Agreement for Participation in Foundation Research: RTOG 3501 Tryhard: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb) for Non-HPV Locally Advanced Head and Neck Cancer with Concurrent Chemoradiation  awarded by American College of Radiology 2012 - 2022
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2019 - 2022
  • Comprehensive Cancer Center Core Support Grant - Create Access to Targeted Cancer Therapy for Underserved Populations (CATCH-UP)  awarded by National Cancer Institute/NIH/DHHS 2019 - 2022
  • Comprehensive Cancer Center Core Support Grant - Integrating Basic Science And Community Outreach And Engagement To Bridge The Transdisciplinary Cancer Research Continuum  awarded by National Cancer Institute/NIH/DHHS 2019 - 2022
  • Deciphering How Esco2 Loss Acts as a Penetrance Modifier  awarded by National Cancer Institute/NIH/DHHS 2017 - 2022
  • Developing Novel Combination Therapies for Pancreatic Cancer  awarded by National Cancer Institute/NIH/DHHS 2016 - 2021
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Private Grant  awarded by IMAGINAB^ 2019 - 2021
  • A New Paradigm: Using PARP Inhibitors to Treat HER2+ Breast Cancer  awarded by Komen (Susan G.) Breast Cancer Foundation 2018 - 2021
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • Developing Therapy for the Treatment of Cholangiocarcinoma  awarded by National Cancer Institute/NIH/DHHS 2016 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • Using the Genomic Profile of High Intermediate Risk Endometrial Cancer Patients to Differentiate Patients at High Risk of Recurrence from the Majority with Low Risk of Recurrence  awarded by FOUNDATION FOR GYNECOLOGIC ONCOLOGY 2016 - 2017
  • Private Grant  awarded by Novartis Pharma AG 2014 - 2017
  • Private Grant  awarded by SUCAMPO PHARMACEUTICALS 2016
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2013 - 2015
  • Private Grant  awarded by ABBVIE INC 2014 - 2015
  • Education And Training

  • Doctor of Medicine, University of Miami 2005
  • Doctor of Philosophy in Molecular Pharmacology, University of Miami 2005
  • Mount Sinai Hospital, Internship 2006
  • Vanderbilt University Medical Center, Residency 2010
  • Full Name

  • Eddy Yang